The common heart of millions of heart is useless, and perhaps risk

This is the discovery of a breakthrough from the “Record trial” with a senior investigator Valentin Vsters, PhD in Medicine, President of Mount Sinai Wester Hart and General Manager of Vascular Central in Spain (CNIC). The results of the study, which could flip the standard treatment model, were presented on Saturday, August 30, during the “Hot Line” session in the European Society for Heart Diseases in Madrid, and was published simultaneously in New England Magazine for Medicine.

In addition, restarting Substudy, published on August 30 in European Heart Magazine, It indicates that women who were treated with beta blockers had a higher risk of death, heart attack, or hospital for heart failure compared to women who do not receive the drug. Men did not have this increasing danger.

“This experience will reshape all international clinical guidelines. It joins the previous historical experiences led by CNIC and Mount Sinai – like Polypill and DAPATAVI, with the SLT2 inhibition associated with TAVI – which has already turned some global methods of cardiovascular disease.”

The safe experience showed Polypill, a single pill that combines three medications – which contain aspirin, Ramberly and Artapastatin – reduce 33 percent of cardiovascular events in patients treated with this after a heart attack. DAPATAVI experience showed both Dapagliflozin and Empagliflozin Medicines – Medicines used to treat diabetes – improves the diagnosis of patients with aortic stenosis treated by transcatheter.

“Re -restarting clinical practice around the world will change,” says CNIC’s lead researcher Bourja Eibz, the scientific director of CNIC, who presented the results. “Currently, more than 80 percent of patients with an uncomplicated heart muscle infarction on beta blockers. Restarting results are one of the most important progress in treating heart attack for decades.”

Although it is generally safe, beta blockers can cause side effects such as fatigue and slow heart (low heart rate), and a sexual dysfunction. For more than 40 years, beta blockers were described as a standard treatment after a heart attack, but its interest in the context of modern treatments was not proven. The restart experience is the largest clinical experience on this topic. The international study was coordinated by CNIC in cooperation with the Mario Negre Institute for Pharmaceutical Research in Milan.

The researchers recorded 8,505 patients through 109 hospitals in Spain and Italy. The participants were randomly appointed to receive or not receive beta blockers after leaving the hospital. All patients received otherwise the current care level and followed an average of nearly four years. The results showed that there are no statistically significant differences between the two groups in the death rates, the repeated heart attack, or in the hospital for the failure of the heart.

The restart of the sub -group found that women are treated with beta blockers have seen more negative events. The results show that women are treated with beta blockers who had an absolute risk of 2.7 percent of deaths compared to those that are not treated with beta blockers within 3.7 years of continuing the study. The high risk is restricted when treating beta blockers on women who have a complete natural heart function after a heart attack (50 percent or higher ventricular expelling. Those who suffer from a moderate deterioration in the heart function did not have a surplus risk of negative results when treated with beta blockers.

“After a heart attack, patients usually prescribe multiple medications, which may make the commitment difficult,” explains Dr. Eibanz. “Beta blockers were added to standard therapy early because they greatly reduced deaths at that time. Its benefits were related to low demand for cardiac oxygen and prevention of irregular heartbeat. But treatments have evolved today. Beta blockers are unclear.

This was the motivation behind restart.

“The experiment was designed to improve the care of heart attacks based on solid scientific evidence and without commercial interests. These results will help simplify the treatment, reduce side effects, and improve the quality of life for thousands of patients every year,” adds Dr. Eibanz.

Restarting without financing the pharmaceutical industry has been made.